pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
BOOST cells
Phase 2 · small molecule · Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.
BOOST cells for Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease. is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code KIBB01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.
- Status
- active
- Trials
- 1